GlobalData on MSN11h
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...
Zacks Investment Research on MSN6h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
More than 70% of dementia diagnoses are for Alzheimers’s. Credit: via Shutterstock. Dementia affects millions of people worldwide, causing a serious impact on the economy and the healthcare system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback